Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.55 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.48 |
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 9/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22444760 | 0.98 | EPHX2 (0.64) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB | |
| SCHEMBL9447706 | 0.98 | EPHX2 (0.64) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB | |
| SCHEMBL5313693 | 0.98 | EPHX2 (0.64) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB | |
| SCHEMBL19066580 | 0.98 | EPHX2 (0.64) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB | |
| SCHEMBL9323113 | 0.94 | EPHX2 (0.56) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB | |
| SCHEMBL31359159 | 0.88 | EPHX2 (0.52) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB | |
| SCHEMBL10504004 | 0.86 | PTGS2 (0.51) | EPHX2PTGS2P4HBSOAT1HPGD | |
| SCHEMBL9810708 | 0.84 | EPHX2 (0.48) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB | |
| SCHEMBL28397899 | 0.82 | EPHX2 (0.50) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB | |
| SCHEMBL28404539 | 0.82 | EPHX2 (0.50) | EPHX2PTGS2CYSLTR2CYSLTR1P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1946708-B | Synthesising method and benzoxathiepine intermediates | PF MEDICAMENT CO LTD | 2011-11-16 | — | — | CN | claimed |
| US-7902381-B2 | Synthesising method and benzoxathiepine intermediates | PIERRE FABRE MEDICAMENT (FR) | 2011-03-08 | — | — | US | claimed |
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | PIERRE FABRE MEDICAMENT (FR) | 2008-09-25 | — | — | US | claimed |
| EP-1735297-B1 | SYNTHESISING METHOD AND BENZOXATHIEPINE INTERMEDIATES | PF MEDICAMENT (FR) | 2007-10-03 | — | — | EP | claimed |
| CN-1946708-A | Synthesising method and benzoxathiepine intermediates | PF MEDICAMENT (FR) | 2007-04-11 | — | — | CN | claimed |
| CN-114644581-B | Amino acid containing aryl thiophenol or aryl selenol modified, recombinant protein, and biosynthesis method and application thereof | 北京惠大生物科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113574041-B | Bisphenol production method and polycarbonate resin production method | 三菱化学株式会社 | 2023-10-13 | — | — | CN | disclosed |
| WO-2020189201-A1 | METHOD FOR PRODUCING BISPHENOL AND METHOD FOR PRODUCING POLYCARBONATE RESIN | 三菱ケミカル株式会社 | 2020-09-24 | — | — | WO | disclosed |
| CN-1946708-B | Synthesising method and benzoxathiepine intermediates | PF MEDICAMENT CO LTD | 2011-11-16 | — | — | CN | disclosed |
| EP-2050769-A2 | Olefin polymerization catalyst and process for olefin polymerization | MITSUI CHEMICALS, INC. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-0990664-B1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD OF POLYMERIZING OLEFIN | MITSUI CHEMICALS INC (JP) | 2009-03-11 | — | — | EP | disclosed |
| CN-1946708-A | Synthesising method and benzoxathiepine intermediates | PF MEDICAMENT (FR) | 2007-04-11 | — | — | CN | disclosed |
| US-6399724-B1 | FOR ALPHA-OLEFINS | MITSUI CHEMICALS, INC. (JP) | 2002-06-04 | — | — | US | disclosed |
| EP-0990664-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD OF POLYMERIZING OLEFIN | Mitsui Chemicals, Inc. (JP) | 2000-04-05 | — | — | EP | disclosed |
| EP-0452302-A1 | PREPARATION ON ORTHO-(ALKYL- OR ARYLTHIO)PHENOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-23 | — | — | EP | disclosed |
| WO-1990005718-A1 | PREPARATION ON ORTHO-(ALKYL- OR ARYLTHIO)PHENOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-31 | — | — | WO | disclosed |
| EP-0369074-A1 | Preparation of ortho-(alkyl-or arylthio) phenols | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4792633-A | REACTING PHENOLS AND DISULFIDES USING ALUMINUM SILICATE CATALYSTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | CYP2F1, CYP2E1, CBR1 | EPHX2 447/4885PTGS2 1659/4885CYSLTR2 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.